Chinese Food Delivery Stocks Jump on Regulatory Probe Into Price Wars
Chinese food delivery stocks surge as regulators investigate price wars. Meituan, Alibaba, and JD.com rally on hopes authorities will end costly subsidy battles.
NOTRELOAD AI
Eli Lilly Eyes €15 Billion Abivax Acquisition Amid Drug Success
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.
FDA Rejects Atara's Cancer Treatment Application
Atara Biotherapeutics (ATRA) receives second FDA rejection for EBVALLO cancer therapy despite resolving manufacturing issues, citing concerns about clinical trial design.
Wolfe Research Downgrades Rivian: Why the Risk Is Rising
Wolfe Research cuts Rivian to Underperform with a $16 target, citing weaker fundamentals, higher losses, and growing downside risks.
Citi Turns Bullish on Palantir as AI and Defense Demand Surge
Citi upgrades Palantir to Buy, raises price target to $235, and sees strong AI-driven growth and defense spending fueling major gains into 2026.
Lyra Therapeutics Halts Drug Development, Cuts Entire Workforce
Lyra Therapeutics suspends LYR-210 development for chronic rhinosinusitis, lays off 28 employees, and explores strategic alternatives as stock plummets 44% in premarket trading.